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Background: Outcome of sirolimus-eluting stent (SES) in patients treated with an antivitamin K (VKA) agent
before the PCI procedure is unknown.
Methods: A total of 7651 patients were selected among 15,147 recipients of SES, included in the worldwide
e-SELECT registry, only from those centers which included at least one patient requiring VKA: 296 were
pretreated with a VKA agent (VKA group), whereas 7355 patients from the same enrolling medical centers
were not (NON-VKA group). The rates of 1) major adverse cardiac events (MACE), including all-cause deaths,
myocardial infarction (MI) and target lesion revascularization, 2) stent thrombosis (ST) and 3) major bleeding
(MB) in the 2 study groups were compared at 1, 6 and 12 months.
Results: The patients in VKA group were on average older as compared to those in NON-VKA group (67.7 ± 9.9
vs.62.9 ± 10.7, P b 0.001). The indications for pre-procedural anticoagulation were atrial ﬁbrillation in 177
(59.8%), presence of a prosthetic valve in 21 (7.1%), embolization of cardiac origin in 17 (5.7%), pulmonary
embolism or deep vein thrombosis in 17 (5.7%), and miscellaneous diagnoses in 64 (21.6%) patients. At
1 year, the rates of MACE and MB were higher in the VKA vs. the NON-VKA group (8.3% and 3% vs. 5.3% and
1.2%, P b 0.04and P b 0.002, respectively). The 1-year rates of deﬁnite and probable ST were remarkably low
in both groups (0.38% vs. 1.1%, p = 0.4).
Conclusions: Selected patients anticoagulated with VKA agent may safely undergo SES implantation. Those
patients may receive a variety of APT regimen at the cost of a moderate increased risk of MB.© 2013 Elsevier Ireland Ltd. All rights reserved.y Department, Hospital Clinic,
08036, Spain. Tel./fax: +34
Ltd. All rights reserved.1. Introduction
Among recipients of coronary artery drug eluting stents (DES), up
to 10% are pretreated with warfarin or other oral antivitamin K (VKA)
agents for the prevention of thromboembolism due to chronic atrial
ﬁbrillation, presence of a prosthetic valve, history of embolization of
Table 1
Baseline characteristics of patients pretreated (VKA group) versus patients untreated






Age, year 67.7 ± 9.9 62.9 ± 10.7 b0.001
Men 228 (77) 5510 (75) 0.45
Body mass index ≥ 30 90 (30.4) 1924 (26.2) 0.11
History of:
Myocardial infarction 128 (43.2) 2500 (34.0) b0.001
Congestive heart failure 56 (18.9) 288 (3.9) b0.001
Percutaneous coronary intervention 130 (43.9) 2592 (35.2) 0.003
Coronary artery bypass graft surgery 56 (18.9) 762 (10.4) 0.001
Diabetes 97 (32.8) 2189 (29.8) 0.27
Insulin-dependent 33 (11.1) 642 (8.7) 0.36
Hypertension 232 (78.4) 5084 (69.1) 0.001
Hyperlipidemia 219 (74.0) 5334 (72.5) 0.64
Current and past smoking 160 (54.0) 4035 (54.9) 0.81
Peripheral vascular disease 44 (14.9) 532 (7.2) b0.001
Cerebral vascular disease 44 (14.9) 313 (4.3) b0.001
Serum creatinine > 2.0 mg/dl 14 (5.2) 178 (2.7) 0.023
Chronic lung disease 24 (8.1) 311 (4.2) 0.003
Mean Charlson comorbidity index score 1.76 ± 1.66 1.10 ± 1.34 b0.001
Charlson index score ≥ 3 73 (24.7) 822 (11.2) b0.001
Coronary arteries with >50% stenoses
0 36 (12.2) 673 (9.2) 0.08
1 228 (77.0) 5569 (75.7) 0.63
2 29 (9.8) 998 (13.6) 0.07
3 3 (1.0) 112 (1.5) 0.63
4 0 3 (0.04) 1.00
1.00
Left ventricular ejection fraction b30% 20 (8.1) 117 (1.9) b0.001
Sinus rhythm 162 (60.5) 6428 (97.3) b0.001
Values are means ± SD or numbers (%) of observations.
2523M. Sabaté et al. / International Journal of Cardiology 168 (2013) 2522–2527cardiac origin, or other indications for long-term, oral anticoagulation
[1]. While a minority, these patients represent a particular challenge
because of the complex antithrombotic regimen needed after a stent
implantation procedure. Of note is that despite their high rate of
comorbidity that can increase the probability of restenosis, these
patients rarely receive a DES implantation, because of the associated
need for long-term anti-platelet therapy with subsequent increase
of bleeding events. However, no data are available for DES safety in
patients under VKA regimen in a real world scenario [2,3].
The purpose of this sub-analysis of the e-SELECT registry was to
compare the 1-year a) clinical outcomes, b) rates of hemorrhagic
and thrombotic events, and c) compliance with dual APT among




The e-SELECT worldwide registry, described in detail elsewhere [4], collected data
between May 2006 and April 2008 in consecutive recipients of ≥1 CYPHER Select® or
CYPHER Select® Plus (Cordis Corporation, Bridgewater, NJ) sirolimus-eluting stents
(SES), implanted at 320 medical centers in 56 countries. The protocol, which speciﬁed
very few exclusion criteria, allowed the implantation of SES for off-label indications,
and all post-procedural medical managements, including antiplatelet therapy (APT),
was according to usual local practices.
Among the 15,147 patients entered in e-SELECT registry, only patients included in
those centers, which enrolled at least 1 patient pre-treated with VKA, were taken into
account in order to avoid any pre-selection confounding factors, which may have
occurred in those centers not enrolling any patients pre-treated with VKA. A total of
7651 patients were therefore selected and in particular we compared 296 patients
pre-treated with a VKA agent (VKA group) with 7355 patients, enrolled at the same
medical centers, not pre-treated with a VKA agent (NON-VKA group). All patients
were followed at 1, 6 and 12 months after the SES implantation procedure. The ethics
committee of each participating medical center approved the protocol and the patients
granted their consent to participate in the registry after the PCI index procedure [1].
2.2. Data collection and management
The data collected by the e-SELECT registry include demographic information,
general health and cardiovascular history, assessment of angina status, co-morbidity,
lesion and procedure characteristics, procedural outcomes, measurements of cardiac
enzymes and serum creatinine, pre- and post-procedural electrocardiogram, cardiac
medications and anti-platelet therapy. Post-procedural clinical observations were
performed up to 1 year of follow-up.
The data were collected electronically at each participating medical center, transferred
to an independent data management organization (KIKA Medical, Nancy, France), and
analyzed by an independent clinical research organization (Cardialysis, Rotterdam, the
Netherlands). The overall consistency and accuracy of data collection were monitored by
an independent organization (Covance, Princeton, NJ) in 20% of the overall sample, at 100
enrolling centers.
2.3. Endpoints of the e-SELECT registry
The primary objective of the registry was to analyze the rates of stent thrombosis
(ST), as deﬁned by the Academic Research Consortium (ARC) up to 1 year of follow-up
[5]. In the present analysis, we also studied the 1-year rates of 1) major bleeding (MB),
according to the STEEPLE deﬁnition (Appendix A) [6], 2) deaths andmyocardial infarction
(MI), and 3) major adverse cardiac events (MACE), a composite endpoint including
a) all-cause deaths, b) MI, and c) percutaneous or surgical target lesion revascularization
(TLR).
2.4. Study organization and supervision
A Steering Committee (Appendix B) planned the analysis of the registry, and pre-
sentations and publications of the results. A Clinical Event Committee (Appendix B)
composed of interventional cardiologists not associated with the sponsor and not par-
ticipants in the registry adjudicated all MACE, MB and acute, subacute, and late ST, by a
systematic review of the data collection forms, and by review of the source documents,
electrocardiograms and angiograms, when necessary.
2.5. Statistical analysis
The sample size calculations of e-SELECT, based on an estimated 3-year rate of
deﬁnite or probable ST, using the ARC deﬁnitions, have been described previously
[1,5]. Standard statistics were used for the description of patients, lesions and proce-
dure characteristics, and of short- and long-term clinical observations. Continuousvariables are presented as means ± standard deviations, and categorical variables as
counts and percentages. Cumulative rates of ST and MB were calculated, using
event-speciﬁc adjusted denominators. Missing values were not imputed. A two-side
p-value b 0.05 was considered signiﬁcant. All statistical analyses were performed,
using the SAS software, version 9.1 or higher (SAS Institute, Cary, NC). The authors of
this manuscript have certiﬁed that they comply with the Principles of Ethical Publishing
in the International Journal of Cardiology.
3. Results
3.1. Baseline clinical and angiographic characteristics
The clinical characteristics of the 2 study groups are shown in
Table 1. The VKA group was, on average, signiﬁcantly older and
exhibited higher rates of concomitant disorders compared with the
NON-VKA group. The indications for pre-procedural anticoagulation
in theVKAgroupwere atrialﬁbrillation in 177 patients (59.8%), presence
of a prosthetic valve in 21 (7.1%), embolization of cardiac origin in 17
(5.7%), pulmonary embolisms or deep vein thrombosis in 17 (5.7%),
and other miscellaneous indications in 64 (21.6%) patients.
The angiographic and procedural characteristics of the 2 study
groups are shown in Table 2. Except for slightly higher prevalence
of restenotic and heavily calciﬁed lesions in the VKA group, no note-
worthy differences were observed.
3.2. Anticoagulation and antiplatelet therapy (Table 3)
The proportions of patients in each study group, who received
single and dual APT and VKA agents before, during and after the SES
procedure, and up to 1-year follow-up are shown in Table 3. In the
VKA group, nearly 60% continued on anticoagulation throughout the
1-year follow-up. It is noteworthy that within this group 30% of
patients also received pre-procedural dual APT. Thereafter, the pro-
portions of patients treated with dual APT decreased to 87%, 75%
and nearly 60% at 1, 6 and 12 months, respectively, after the index
SES implant procedure. Conversely, in the NON-VKA group, nearly
100%, 95% and 80% of patients received dual APT at 1, 6 and 12 months,
Table 2
Lesion and procedure characteristics in 296 patients treated (VKA group) versus 7355
patients untreated (NON-VKA group) with an antivitamin K agent.
VKA group










2.93 ± 0.45 2.91 ± 0.46 0.39
Pre-procedural percent
stenosisa
83.9 ± 12.8 84.5 ± 12.3 0.39
Lesion length, mma 19.9 ± 12.5 19.9 ± 11.8 0.98
Target lesion types
In native coronary artery 366 (94.3) 9696 (97.8) b0.001
Restenoticb 74 (19.3) 1337 (13.6) 0.002
Length ≥ 20 mmc 166 (43.3) 4257 (43.3) 1.00
Heavily calciﬁedb 28 (8.2) 376 (4.3) 0.002
Procedural characteristics
Numbers per patient
Vessels treated 1.2 ± 0.4 1.2 ± 0.4 0.29
Lesions treated 1.3 ± 0.6 1.3 ± 0.6 0.37
Stents implanted 1.6 ± 0.8 1.6 ± 0.9 0.41
Total stent length, mm
Per lesion 24.6 ± 13.4 25.0 ± 13.3 0.62
Per patient 32.2 ± 20.8 33.7 ± 21.5 0.23
Direct stenting 144 (37.5) 3533 (35.9) 0.58
Pre-dilatation 240 (62.5) 6314 (64.1) 0.45
Post-dilatation 166 (37.6) 4586 (40.3) 0.17
Intravascular ultrasound
imaging
18 (4.8) 277 (2.8) b0.001
Duration of hospitalization
(days)
3.7 ± 4.6 3.1 ± 3.2 0.002
Values are means ± SD, or numbers (%) of observation.
a Visual estimate.
b Calculated per lesion.
c Calculated per patient. Table 3







Preprocedural (n = 296) (n = 7355)
Antiplatelet regimens
None 95 (32.4) 692 (9.4) b0.001
Aspirin or thienopyridine only 111 (37.9) 2539 (34.7) 0.29
Dual regimen 87 (29.4) 4082 (55.8) b0.001
VKA 296 (100) 0 na
Intraprocedural (n = 294) (n = 7340)
Antiplatelet regimens
Aspirin or thienopyridine only 46 (15.7) 729 (10.0) 0.003
Dual regimen 227 (77.5) 5982 (81.7) 0.08
Glycoprotein IIb/IIIa inhibitor 47 (16.0) 1157 (15.8) 0.935
Unfractionated or low-molecular heparin 272 (92.5) 6700 (91.3) 0.526
Discharge from the hospital (n = 294) (n = 7348)
Antiplatelet regimens
None 1 (0.34) 1 (0.01) 0.08
Aspirin or thienopyridine only 30 (10.2) 74 (1.0) b0.001
Dual regimen 259 (88.1) 7238 (98.5) b0.001
VKA with or without antiplatelet regimen 184 (62.6) 85 (1.2) b0.0001
1 month (n = 282) (n = 7026)
Antiplatelet regimens
None 1 (0.36) 18 (0.26) 0.53
Aspirin or thienopyridine only 36 (12.8) 98 (1.4) b0.001
Dual regimen 245 (86.9) 6894 (98.1) b0.001
VKA or other anticoagulant 163 (57.8) 104 (1.5) b0.001
6 months (n = 280) (n = 6799)
Antiplatelet regimens
None 7 (2.5) 40 (0.6) 0.002
Aspirin or thienopyridine only 63 (22.5) 307 (4.5) b0.001
Dual regimen 210 (75.0) 6.448 (94.8) b0.001
VKA with or other anticoagulant 161 (57.5) 124 (1.8) b0.001
12 months (n = 264) (n = 6748)
Antiplatelet regimens
None 17 (6.4) 83 (1.2) b0.001
Aspirin or thienopyridine only 93 (35.2) 1356 (11.0) b0.001
Dual regimen 154 (58.3) 5304 (78.6) b0.001
VKA with or other anticoagulant 151 (57.2) 151 (2.2) b0.001
Values are numbers (%) of observations; VKA = antivitamin K agent.
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procedure.
3.3. Clinical outcomes, stent thrombosis and major bleeding (Table 4 and
Fig. 1)
Among the 296 patients included in the VKA group, 1-, 6- and
12-month follow-ups were completed in 99.7%, 98.6% and 94.0% of
the patients, respectively. Among the 7355 patients included in the
NON-VKA group, follow-up was completed in 99.3%, 98.1% and
94.8% of the patients at 1-, 6- and 12-months, respectively.
The MACE rate was low in both study groups, but was signiﬁcantly
higher in the VKA than in the NON-VKA (8.3% vs. 5.3%, p = 0.04)
group at 12 months follow-up (Fig. 1). Similarly, the rates of MB
were low in both groups, though it was 2-fold higher at 1 month
(1.0% vs. 0.5%, p = 0.19) and nearly 3-fold higher at 6 (2.1% vs.
0.8%, p = 0.036) and 12 months (3.0% vs. 1.2%, p = 0.002) in the
VKA than in the NON-VKA group (Table 4).
The rates of ST as deﬁned by ARC were remarkably low in both
study groups. It is particularly noteworthy that, in the VKA group,
the rate of acute and sub-acute ST was 0%, and that a single deﬁnite
ST (0.38%) was observed at 1 year. In the NON-VKA group, the rates
of acute, subacute and late deﬁnite/probable ST were also b1%
(Table 5).
4. Discussion
Several observations can be made in this analysis. First, patients
requiring VKA treatment had a higher prevalence of concomitant dis-
orders (high Charlson comorbidity index) as compared to patients
non-VKA treated, associated with a higher incidence of MACE during
follow-up. Secondly, selected patients requiring VKA treatment can
be safely treated with DESwith relatively low incidence of stent throm-
bosis, despite a lower use of dual antiplatelet therapy compared withpatients non-VKA treated. Finally, despite their lower use of dual APT,
patients requiring VKA treatment do exhibit a higher rate of major
bleeding when compared with patients without VKA treatment.
Previous studies in patients with atrial ﬁbrillation under VKA
treatment and receiving PCI have shown a MACE rate around 23%
and 36% at 1 and 2 years follow-up [7–9]. This high rate of MACE
has been explained by the high-risk proﬁle of this population, with
co-morbid conditions and subsequently high risk of ischemic and
bleeding events [10–12]. The present sub-analysis from e-SELECT reg-
istry conﬁrms this higher rate of MACE in VKA patients as compared
to non-VKA patients, further supporting the role of baseline clinical
proﬁle (high Charlson index) in determining their worse clinical out-
come [9]. It is noteworthy that whereas no differences in MACE or
bleeding events were present between the two groups at 1-month
follow-up, they became evident at 6 months, suggesting that these
events need mid-time follow-up to accrue in patients VKA-treated.
In contrast with previous studies, our analysis extended to a wider
population, including patients under VKA-treatment not only for atrial
ﬁbrillation, but also for other clinical reasons (e.g. prosthetic valve).
In addition, it is important to note that the MACE rate in the VKA
group was in our analysis consistently lower (8.3% at 1 year) as com-
pared to previous reports [7,8]. It may be argued that use of SES in our
population could have played a major role in this relatively lowMACE
rate. Previous reports indeed did include a heterogeneous population
with regard to the drug-eluting stent implanted, having different late
loss and therefore different MACE rates. In the study of Rogacka et al.,
for instance, only 59.2% were SES, 35.2% were paclitaxel-eluting
stents and the rest were BMS. This resulted in a MACE and TLR rates
of 19.7% and 12.7%, respectively, in the DES group [7]. Ruiz-Nodar
Table 4
Cumulative rates of adverse clinical events at 30 days, 6 months, and 1 year of follow-up.
Study group P-value
VKA NON-VKA
1 month n = 294 n = 7298
Death 2 (0.68) 27 (0.37) 0.31
Cardiac 1 (0.34) 23 (0.31) 0.61
Myocardial infarction 2 (0.68) 85 (1.2) 0.78
Q-wave 0 14 (0.2) 1.00
Target lesion revascularization 2 (0.68) 33 (0.45) 0.39
Percutaneous 2 (0.68) 33 (0.45)
Major adverse cardiovascular eventsa 5 (1.7) 115 (1.6) 0.80
Major bleeding 3 (1.0) 36 (0.5) 0.19
6 months n = 291 n = 7203
Death 6 (2.0) 65 (0.9) 0.057
Cardiac 2 (0.7) 41 (0.6) 0.68
Myocardial infarction 4 (1.4) 115 (1.6) 1.00
Q-wave 1 (0.4) 20 (0.28)
Target lesion revascularization 7 (2.5) 96 (1.34) 0.12
Percutaneous 7 (2.5) 91 (1.27)
Major adverse cardiovascular eventsa 15 (5.2) 225 (3.1) 0.06
Major bleeding 6 (2.1) 58 (0.8) 0.036
12 months n = 277 n = 6941
Death 12 (4.3) 119 (1.7) 0.004
Cardiac 5 (1.8) 68 (0.99) 0.20
Myocardial infarction 4 (1.5) 144 (2.1) 0.66
Q-wave 1 (0.4) 25 (0.4) 1.00
Target lesion revascularization 9 (3.4) 179 (2.6) 0.43
Percutaneous 9 (3.4) 164 (2.4) 0.31
Major adverse cardiovascular eventsa 23 (8.3) 367 (5.3) 0.04
Major bleeding 8 (3.0) 83 (1.2) 0.002
Values are numbers (%) of observations.
a Patients who experienced >1 MACE are counted only once.
Table 5
Cumulative rates of stent thromboses at 30 days, 6 months, and 1 year of follow-up.
Study group P
VKA NON-VKA
0–24-h (acute) n = 296 n = 7343
Stent thrombosis
Deﬁnite 0 3 (0.04) 1.000
Probable 0 3 (0.04) 1.000
Possible 0 0 –
>24 h–30 days (subacute) n = 292 n = 7275
Stent thrombosis
Deﬁnite 0 30 (0.41) 0.6296
Probable 0 17 (0.23) 1.000
Possible 0 0 –
>30 days–12 months (late) n = 266 n = 6835
Stent thrombosis
Deﬁnite 1 (0.38) 21 (0.31) 1.000
Probable 0 8 (0.12) 1.000
Possible 2 (0.75) 25 (0.37) 1.000
Values are numbers (%) of observations.
2525M. Sabaté et al. / International Journal of Cardiology 168 (2013) 2522–2527et al. in a matched comparison between BMS and DES did not specify
which kind of DES platform was implanted, ﬁnding no differences in
terms of MACE between the two groups [13]. On the contrary, our
analysis represents the largest report on use of a sirolimus-eluting
platform in this population. It should be also considered that a bias
in the selection process by the operators of patients, who would
have beneﬁted from DES, and the withdrawal of VKA regimen in
almost half of the patients at 12-month may have inﬂuenced the good
outcome in the present report as compared to the previous ones.Log-rank test p=0.03
Log-rank test p=0.46
Fig. 1. Kaplan–Meier curves of MACE, all-cause death, myocardial infarction and target lesio
infarction; TLR = target lesion revascularization; VKA = anti-vitamin K treatment.SES have previously proved to be able to reduce target lesion
revascularization in comparison with BMS, not only in favorable
lesions and patients [14], but also in more complex lesions, such as
total chronic coronary occlusions, vessel restenosis and/or diabetic
patients [15–17]. Stenting with SES has been also recently showed
as an effective therapeutic option in elderly patients, with acceptable
rates of complications and a very low rate of repeat revascularization
[18]. Patients under VKA treatment resemble elderly patients, being a
population seldom included in clinical trial testing DES, with comor-
bidity and high risk of bleeding, worsened by a prolonged antiplatelet
therapy. Nevertheless, our ﬁndings showed that they may safely
undergo DES implantation and be treatedwith dual antiplatelet therapy
at the cost of a moderately increased risk of bleeding. It is noteworthy
that though a lower usage of dual antiplatelet therapy in VKA than
non-VKA patients, the rate of stent thrombosis was very low and com-
parable between the two groups, further remarking the good safety
proﬁle of the SES platform even compared to the 2nd generation DES
[19–21]. Conversely, the incidence of bleeding was, as expected, higher
in VKA than in NON-VKA group and comparable to previous studiesLog-rank test p=0.014
Log-rank test p=0.47
n revascularization survival between the VKA and NON-VKA groups. MI = myocardial
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ing in order to reduce the major bleeding associated to anti vitamin K
agents [24]. Novel trials combining DES and these new agents would
be required. Recent consensus did not currently discourage DES use in
an VKA population, especially for those patients at low-moderate risk
of hemorrhagic events and admitted for acute coronary syndrome,
which already implies per se a 12-month duration of antiplatelet therapy
independently from the stent implanted [25]. Recently, theWoest study
has also shown the safety of using only clopidogrel on the top of VKA
agent instead of DAT, without any increase in stent thrombosis and
with strong decrease in bleeding event at 1-year follow-up [26].
4.1. Limitations
This analysis is limited by its registry design and by its post-hoc
nature. The clinical follow-up, limited to 1 year, precluded the evalu-
ation of very late stent thrombosis and late adverse events. The type
of selection process applied in each center is unknown: some of the
sicker patients on VKA and those with the highest perceived bleeding
risk may have been treated with a BMS and were thus not included.
For this reason, the study population is a much selected one and the
present ﬁndings do not necessarily apply to all patients on VKA who
require coronary stenting. Finally, the e-SELECT registry was a real
world registrywithout a predeﬁned antithrombotic regimen in patients
on VKA. Therefore, multiple treatment combinations were observed
during hospitalization and at discharged from the index procedure.
For this reason, it was not possible to deﬁne the optimal antithrombotic
combination following SES implantation in these high risk patients.
5. Conclusions
Selected patients anticoagulated with VKA agent may safely undergo
SES implantation. Those patientsmay receive a variety of APT regimen at
the cost of a moderate increased risk of MB. The optimal regimen, using
new anticoagulant drugs in association with APT after SES implantation
needs to be determined in future studies.
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Appendix A. Classiﬁcation of major versus minor bleeding events
used for this analysis (Montalescot et al. [6])Major bleeding*
▪ Fatal
▪ Retroperitoneal, intracranial, or intraocular
▪ Compromising hemodynamic function and requiring speciﬁc treatment
▪ Requiring a surgical or endoscopic intervention, or the decompression of a
closed space to stop or control the event
▪ Clinically overt, requiring the transfusion of ≥1 unit of packed red cells or
whole blood
▪ Clinically overt, causing a ≥3 g/dl (or ≥10%) decrease in hemoglobin.
Minor bleeding†
▪ Non-traumatic gross hematuria
▪ Epistaxis that is prolonged, recurrent, or requiring an intervention
▪ Gastrointestinal hemorrhage
▪ Hemoptysis
▪ Sub conjunctival hemorrhage
▪ Hematoma > 5 cm in diameter or prompting a new or longer hospitalization
▪ Clinically overt and causing a 2 to 3 g/dl decrease in hemoglobin
▪ Requiring the administration of protamine sulfate
⁎ Deﬁned as bleeding that met ≥1criterion.
† Deﬁned as bleeding that met a) no criterion for major bleeding, and b) ≥1 minor
bleeding criterion.Appendix B. Organization of the e-SELECT registry
Steering Committee: Philip Urban, MD (Chair) Geneva, Switzerland;
Alexander Abizaid, MD, Sao Paolo, Brazil; Adrian Banning, MD, Oxford,
UK; Antonio Bartorelli, MD, Milan, Italy; Vladimir Dzavik, MD, Toronto,
Canada; Steven Ellis MD, Cleveland, OH, USA; Runlin Gao, MD, Beijing,
China; David Holmes MD, Rochester, MN, USA; Myung Ho Jeong, MD,
Gwang Ju, Korea; Victor Legrand, MD, Liege, Belgium; Franz-Josef
Neumann, MD, Bad Krozingen, Germany; Christian Spaulding, MD,
Paris, France; and Stephen Worthley, MD, Adelaide, Australia.
Clinical event Committee: Emanuele Barbato, MD, Alst, Belgium;
Alaide Chieffo, MD, Milano, Italy; Christoph Naber, MD, Essen, Germany;
Lisette Okkels Jensen, MD, Odense, Denmark; Koichi Sano MD,
Saitama-ken, Japan; and Vankeepvram Srinivas, MD, New York, NY, USA.
Electronic data capture and database management: KIKA Medical,
Nancy, France.
Statistical analysis: Cardialysis, Rotterdam, The Netherlands
Study sites monitoring: Covance Clinical Research Organization,
Princeton, NJReferences
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